Webinars

PELOAcademy | Scalable EV Isolation and High-Quality Purification with Advanced Technologies

Presented by Prof. Dr. Sehyun Shin, Korea University & CEO, Microgentas Inc., Seoul, Korea

Learn about innovative approaches for scalable EV isolation and high-quality purification, focusing on the integration of charge-based filtration (ExoFilter) with other technologies like TFF and LipoFilter. Learn how ExoFilter, combined with Tangential Flow Filtration (ExoTFF), and the lipoprotein-specific LipoFilter, optimize EV yield and purity.

Cardiosight®-S exhibits a purity exceeding 95% of cardiac markers and demonstrates a dose-dependent response to drugs targeting electrophysiological ion channels, suggesting high physiological relevance of the cells.

PELOAcademy | Compatibility of hiPSC-derived cardiomyocytes in cardiac safety assessment of drugs

Presented by Jieun An, Ph.D., Senior scientist, NEXEL Co, Seoul, Korea

We introduce NEXEL’s Cardiosight®-S (hiPSC-CMs), aligning with the updated ICH E14/S7B guidelines, and provide practical examples of its applications. Cardiosight®-S exhibits a purity exceeding 95% of cardiac markers and demonstrates a dose-dependent response to drugs targeting electrophysiological ion channels, suggesting high physiological relevance of the cells.

PELOAcademy | Humanized Multi-Organoid Disease Models Advancing 3D drug development models

Presented by Dr. Raquel Sousa, Research and Development Scientist, abc biopply, Switzerland

Traditional in vitro and in vivo disease models have demonstrated significant limitations in accurately predicting patient responses to treatment. Efforts have been made to humanize mouse models in order to better reflect aspects of human physiology and immunology, these attempts have had limited success. Learn about the breakthrough in humanizing 3D cell models through the 3D CoSeedis multi-organoid in-chip technology™.

Isolation of Cells from Fat_60th Anniversary of Martin Rodbell's Seminal Publication

Presented by Stuart K. Williams, PhD, University of Louisville, Scottsdale, Arizona, USA

Explore the evolution of methods for isolating adipocytes and adipose-derived stromal vascular fraction (ADSVF) cells. Factors responsible for the variability in ADSVF cells include species and anatomic differences in fat tissue, mincing, tissue dissociation enzymes, agitation, filtration, and centrifugation. Technologies used to characterize these cells will also be discussed, including cell counting, viability, and cellular markers.

Collagenase Selection & Process Optimization for High Yield Hepatocyte Isolation

Presented by Rafal Witek, Senior Director of R&D Engineering, Dimension Inx, USA, and our partner VitaCyte, USA

This webinar reviews best practices for building a high-yield primary human and animal hepatocyte isolation process with the inclusion of collagenase selection and buffer optimization. The webinar will cover process variabilities that impact isolation and how to overcome them to generate high-quality and high-viability hepatocytes. The information presented will enable participants to build their isolation, resulting in a high success rate and hepatocyte yield.

PELOAcademy | Adipocyte spheroids: Obesity-related Research in a more in vivo-like Environment

Presented by Dr. rer. nat. Anita Wagner, Chair of Molecular Nutritional Medicine, Technical University of Munich

Utilizing a three-dimensional environment to cultivate adipocytes is a method that more accurately replicates in vivo conditions compared to conventional two-dimensional cultures. This valuable computational tool can be employed to analyze dynamic interactions within the WAT microenvironment, offering insights into adipose tissue biology and identifying potential therapeutic targets for metabolic disorders.

EMERGE Epsiode 19 | Deep proteomic insight into disease biology identifies age-specific vulnerabilities in acute leukemia

Presented by Sudip Ghosh, Lund Stem Cell Center, Lund University, Sweden and Resyn Biosciences, South Africa

Infant and adult MLL1/KMT2A-rearranged (MLLr) leukemia represents a disease with a dismal prognosis. We revealed early proteomic events of MLL::ENL-mediated transformation in fetal and adult blood progenitors. Adult pre-leukemic cells are mainly characterized by retained myeloid features and downregulation of ribosomal and metabolic proteins, expression of MLL::ENL in fetal lymphomyeloid multipotent progenitors (LMPPs) leads e.g. to the enrichment of translation-associated and histone deacetylases signaling proteins.

EMERGE Epsiode 18 | Systematic optimization of automated phosphopeptide enrichment for high-sensitivity phosphoproteomics

Presented by Patricia Bortel, BSc, MSc, Institut für Analytische Chemie Wien, and hosted by ReSyn, South Africa

Improving coverage, robustness, and sensitivity is crucial for routine phosphoproteomics analysis by single-shot liquid chromatography tandem mass spectrometry (LC-MS/MS) from minimal peptide input. The webinar focuses on the systematic optimization of key experimental parameters for automated on-bead phosphopeptide sample preparations, low-input samples, pinpointing critical variables influencing the resulting phosphoproteome coverage.

EMERGE Epsiode 17 | Streamlined proteome-wide identification of drug targets indicates organ-specific engagement

Presented by Tanveer Batth, Novo Nordisk, Center for Protein Research, Danmark and ReSyn Biosciences, South Africa

Proteins are the primary targets of almost all small-molecule drugs. Even drugs designed with high specificity may interact with multiple proteins that are not initially targeted. Discovering these potential interactions is crucial for the development and repurposing of drugs. We report the development of a label-free quantitative proteomics approach that enables proteome-wide screening of small organic molecules in a scalable, reproducible, and rapid manner by streamlining the proteome integral solubility alteration (PISA) assay. Tanveer is a researcher at the NNF CPR in Denmark.

EMERGE Episode 16 | The potential of plasma HLA peptides beyond neoepitopes

Presented by Maria Wahle, PhD student, Max-Planck-Institute of Biochemistry, Munich and and ReSyn Biosciences, South Africa

Soluble HLA (sHLA) peptides are thought to have great potential as biomarkers for different diseases such as cancer. However, efficient enrichment of sHLA peptides from body fluids like plasma has been a bottleneck, requiring 3-5 ml per patient. Maria presents IMBAS-MS, an automated magnetic bead-based workflow for the efficient enrichment of HLA protein-peptide complexes. The core of IMBAS-MS is the combination of biotinylated antibodies immobilized on streptavidin magnetic beads allowing for an automated one-pot enrichment from only 200 µl of plasma.

Islet Isolation Success of Chronic Pancreatitis Pancreas & Brain-Dead Donor Pancreas Intended for Auto & Allo-Transplantation

Presented by Balamurugan N. Appakalai, PhD, Nationwide Children’s Hospital and hosted by VitaCyte, Indianapolis, USA

Recovery of human islets from pancreata recovered from brain-dead donors and chronic pancreatitis patients for subsequent transplantation requires consideration of different factors. Isolating islets from pancreata from donors with a high BMI has a higher probability of success than isolating islets from donors with a low BMI. The choice of neutral protease and control of the ratio of collagenase/protease activities is critical since it affects the percentages of free and embedded islets.

PELOAcademy | Engineering Cardiac Microtissues for Cell Therapy

Presented by Dr. Kurt Pfannkuche, PD, The Marga-and-Walter-Boll-Laboratory for Cardiac Tissue Engineering, University of Cologne

Induced pluripotent stem cells (iPSCs) can be differentiated into heart muscle cells in vitro and open up new possibilities for the development of therapies for myocardial infarction. However, the transplantation of pure cardiac muscle cells from iPSCs has the disadvantage that only a small proportion of the cells remain in the tissue. The presentation will show approaches for the experimental production of cardiac microtissues for cell therapy.

Please ask for details e.g. the recording via email to anne.osman@pelobiotech.com or come to the Conference on June 27 to meet Dr. Pfannkuche face-to-face.